Inactivation of Caspase-1 in Rodent Brain: A Novel Anticonvulsive Strategy by Ravizza, Teresa et al.
Epilepsia, 47(7):1160–1168, 2006
Blackwell Publishing, Inc.
C© 2006 International League Against Epilepsy
Inactivation of Caspase-1 in Rodent Brain: A Novel
Anticonvulsive Strategy
∗Teresa Ravizza, †Sian-Marie Lucas, ∗Silvia Balosso, ‡Liliana Bernardino, §George Ku,∗Francesco Noe´, ‡Joao Malva, §John C. R. Randle, †Stuart Allan, and ∗Annamaria Vezzani
∗Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy; †Faculty of Life Sciences,
University of Manchester, Manchester, United Kingdom; ‡Center for Neuroscience and Cell Biology, Institute of Biochemistry,
University of Coimbra, Portugal; and §Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts, U.S.A.
Summary: Purpose: Cytokines and related inflammatory me-
diators are rapidly synthesized in the brain during seizures. We
previously found that intracerebral administration of interleukin-
1 (IL-1)-β has proconvulsant effects, whereas its endogenous
receptor antagonist (IL-1Ra) mediates potent anticonvulsant ac-
tions in various models of limbic seizures. In this study, we inves-
tigated whether seizures can be effectively inhibited by block-
ing the brain production of IL-1β, by using selective inhibitors
of interleukin-converting enzyme (ICE/caspase-1) or through
caspase-1 gene deletion.
Methods: Caspase-1 was selectively blocked by using pral-
nacasan or VX-765. IL-1β release was induced in mouse organ-
otypic hippocampal slice cultures by proinflammatory stimuli
[lipopolysaccaride (LPS) + adenosine triphosphate (ATP)] and
measured with enzyme-linked immunosorbent assay (ELISA).
IL-1β production during seizures was measured in the rat hip-
pocampus by Western blot. Seizures were induced in freely mov-
ing mice and rats by intrahippocampal injection of kainic acid
and recorded by EEG analysis.
Results: Caspase-1 inhibition reduced the release of IL-1β in
organotypic slices exposed to LPS+ATP. Administration of pral-
nacasan (intracerebroventricular, 50 μg) or VX-765 (intraperi-
toneal, 25–200 mg/kg) to rats blocked seizure-induced produc-
tion of IL-1β in the hippocampus, and resulted in a twofold
delay in seizure onset and 50% reduction in seizure duration.
Mice with caspase-1 gene deletion showed a 70% reduction in
seizures and an approximate fourfold delay in their onset.
Conclusions: Inhibition of caspase-1 represents an ef-
fective and novel anticonvulsive strategy, which acts by
selectively reducing the brain availability of IL-1β. Key
Words: Cytokines—Epilepsy—Inflammation—Interleukin-
1β—Glia—Hippocampus.
Inflammatory mediators are rapidly induced in rodent
brain both in glia and in neurons during seizures (1–7). In
particular, intracerebral application of intereukin-1β(IL-
1β) prolongs the duration of electrographic (EEG) and be-
havioral seizures in rodents (3,6). Conversely, IL-1Ra, a
naturally occurring antagonist of IL-1β (8), mediates pow-
erful anticonvulsant effects (4,6), and mice overexpressing
IL-1Ra in astrocytes show a dramatically reduced suscep-
tibility to seizures (6,9). Recently, the threshold to seizure
induction in experimental models of febrile convulsions,
was shown to be decreased by intracerebral IL-1β injec-
tion and raised in IL-1 receptor–deficient mice or after
delivery of IL-1Ra (10,11). These findings indicate that
an increase in IL-1β levels in the brain, as occurs during
seizures, has proconvulsant effects.
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This evidence prompted us to study whether preventing
the brain production of IL-1β during seizures results in
significant anticonvulsive effects. This goal was achieved
by using selective inhibitors or gene deletion of caspase-
1 (12–14), the key enzyme specifically involved in the




Animals were housed at a constant temperature (23◦C)
and relative humidity (60%) with free access to food and
water and a fixed 12-h light/dark cycle. Procedures involv-
ing animals and their care were conducted in conformity
with the institutional guidelines that are in compliance
with national (D.L.n.116, G.U., suppl.40, Feb. 18, 1992;
UK legislation under the 1986 Animals Scientific Proce-
dures Act) and international laws and policies (EEC Coun-
cil Directive 86/609, OJ L 358, 1, Dec.12, 1987; Guide for
the Care and Use of Laboratory Animals, U.S. National
Research Council, 1996).
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Rats
Male Sprague–Dawley rats (250–280 g) were pur-
chased from Charles River (Calco, Italy).
Mice
Caspase-1 knockout (KO) mice and their wild-type
strain (C57BL6/SV129, ∼24 g) were kindly supplied by
Dr. W. Wong (BASF Bioresearch Corporation, Worcester,
MA, U.S.A.). Wild-type and KO animals were bred sep-
arately as homozygous groups from breeding couples of
the same genetic background and at the time of the study
were at generation 12 and 15, respectively.
Caspase-1 KO mice have been extensively character-
ized previously: they develop normally and are healthy
and fertile; they are highly resistant to the lethal effects of
lipopolysaccharide (LPS), and their macrophages exhibit
a severe defect in the production of mature IL-1β (15).
Placement of cannula and electrodes for EEG
recordings
Rats
Rats were surgically implanted with cannulae and elec-
trodes under stereotaxic guidance as previously described
(3). In brief, rats were deeply anesthetized by using Equi-
thesin (1% phenobarbital and 4% chloral hydrate; 3 ml/kg,
intraperitoneally, i.p.). A ground lead was positioned over
the nasal sinus, and two screw electrodes were placed bi-
laterally over the parietal cortex. Bipolar nichrome wire-
insulated electrodes (60 μm) were implanted bilaterally
into the dorsal hippocampus (septal pole) at the following
coordinates from bregma: mm, nose bar –2.5, AP –3.5, L
±2.4 and 3.0 below dura mater. A 22-gauge guide cannula
was unilaterally positioned on top of the dura and glued to
one of the depth electrodes for intrahippocampal injection
of kainic acid. In some rats, an additional guide cannula
was unilaterally positioned on top of the dura mater for
intracerebroventricular (icv) injection of pralnacasan (in
mm from bregma, nose bar –2.5; AP –1; L +1.5). The
electrodes were connected to a multipin socket (March
Electronics, Bohemia, NY, U.S.A.) and, together with the
injection cannula, were secured to the skull by acrylic
dental cement.
Mice
Mice were anesthetized by using 5% halothane (Con-
cord Pharmaceuticals Ltd, Dunmow, Essex, U.K.) with
oxygen as the carrier gas at a flow rate of 0.4 L/min. Anes-
thesia was maintained by inhalation of 1.5–2% halothane
with oxygen. A ground lead was positioned over the nasal
sinus. The stainless-steel recording electrode of an ETA-
F20 small-animal telemetry device (Data Sciences Inter-
national, St. Paul, MN, U.S.A.) was unilaterally implanted
into the septal pole of the dorsal hippocampus (in mm
from bregma, nose bar 0; AP −1.9; L −1.5 and 1.5 below
dura mater), with the transmitter body being placed sub-
cutaneously on the animal’s flank. A 22-gauge injection
cannula was attached to the depth electrode and positioned
on top of the dura mater for the intrahippocampal injection
of kainic acid. The experiments were performed ≥3 days
after surgery to allow the animals to recover.
EEG recordings and injection of drugs
The procedures for recording the EEG and intracerebral
injection of drugs in freely moving rats or mice have been
previously described (3,6).
Kainic acid
Kainic acid (Sigma-Aldrich, St. Louis, MO, U.S.A.)
was dissolved in 0.5 μl phosphate-buffered saline (PBS,
pH 7.4) and injected in the mouse (14 ng) or rat (40 ng)
dorsal hippocampus unilaterally (1 μl/min), by using a
needle protruding 1.5 or 3.0 mm, respectively, from the
guide cannula.
This dose of kainic acid was chosen to induce recurrent
EEG epileptic activity composed of ictal episodes (EEG
seizures) and spiking activity in 100% of animals without
mortality.
Pralnacasan and VX-765
Pralnacasan (Vertex Pharmaceuticals, Inc., Cambridge,
MA, U.S.A.) was dissolved in 20% cremophor (25 μg in
4 μl, the maximal concentration soluble in the injected
volume) and injected icv in rats or mice, 45 min and 10
min before intrahippocampal injection of kainic acid. In
preliminary experiments, pralnacasan was also adminis-
tered in a single dose (12.5 or 25 μg in 4 μl), 45 min
before kainic acid. VX-765 (25, 50, 200 mg/kg; Vertex
Pharmaceuticals) was dissolved in 20% cremophor and
injected ip in rats once a day for 3 consecutive days. On
the fourth day, rats received VX-765, 45 min and 10 min
before intrahippocampal injection of kainic acid. Respec-
tive controls were similarly injected with vehicle before
kainic acid.
The correct positioning of the injection needle and elec-
trodes was verified by Nissl staining of 40-μm cryostat
coronal brain sections in all the animals, 24 h after kainic
acid injection (not shown). In mice, no evidence of neu-
ronal cell loss was observed in any experimental condition;
in rats treated with kainic acid, we observed the typical
pattern of pyramidal cell loss restricted to CA3 area, as
previously reported in detail (3,16). The unspecific dam-
age restricted to the insertion of injection needle and the
electrode tracks was similar in control and experimental
animals. All pharmacologic experiments were carried out
between 9.00 a.m. and 1.00 p.m.
Seizure assessment and quantification
Rats
EEG seizures induced by intrahippocampal injection
of kainic acid in rats have been extensively described
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(3). In brief, a 30-min recording was done before kainic
acid injection to assess the basal EEG pattern. Record-
ing was stopped after 180 min from kainate injection, a
time at which seizure activity was absent for ≥30 min
in all the animals. Ictal episodes were characterized by
high-frequency and/or multispike complexes and/or high-
voltage synchronized spikes simultaneously occurring in
the injected hippocampus. Spiking activity was typically
observed after seizures subsided (3). The EEG recording
of each animal was analyzed visually by two independent
investigators blinded to the treatments to detect any activ-
ity different from baseline. Seizure activity was quantified
by counting the time to seizure onset (elapsed from kainic
acid injection to the occurrence of the first EEG seizure)
and the total number and duration of seizures (counted by
summing the duration of every ictal episode during the
EEG recording period) (3). Shortly after its administra-
tion, kainic acid induced stereotyped behaviors such as
sniffing and gnawing. “Wet-dog shakes” were often ob-
served shortly after kainate injection and during seizures.
Mice
EEG was acquired by remote telemetry. The signal from
the recording depth electrode was transmitted by radiofre-
quency and captured by a receiver pad (Data Sciences)
under the cage of each animal. This signal was relayed to
a computer that sampled and recorded the analogue output
by using Dataquest A.R.T. Analog (Data Sciences). The
EEG patterns were recorded and visualized by using Data-
pac 2K2 (RUN Technologies, Laguna Hills, CA, U.S.A.).
A baseline recording of ≥30 minutes was acquired be-
fore drug treatments. Recording was stopped after 180
min from kainate injection, a time at which seizure ac-
tivity was absent for ≥30 min in all the animals. Seizure
activity was quantified as in the rat.
Western blot analysis
Different groups of rats (n = 3 in each treatment group)
were treated icv with pralnacasan or its vehicle given
alone, or before intrahippocampal application of kainic
acid (see earlier). Ninety minutes after the onset of EEG
seizures, when pralnacasan effect on seizures was evi-
dent (see Results), experimental rats and their controls
were decapitated. The injected hippocampi were dissected
out at 4◦C and homogenized in 20 mM Tris-HCl buffer
(pH 7.4), containing 1 mM EDTA, 5 mM EGTA, 1 mM
Na-vanadate, 2 μg/μl aprotinin, 1 μg/μl pepstatin, and
2 μg/μl leupeptin (30 mg tissue/150 μl homogenization
buffer). Total proteins (150 μg per lane; Bio-Rad Pro-
tein Assay, Bio-Rad Labs, Munich, Germany) were sep-
arated by using sodium dodecylsulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), 10% acrylamide, and
each sample was run in duplicate. Proteins were trans-
ferred to Hybond nitrocellulose membranes by elec-
troblotting. For immunoblotting, we used anti-rat IL-1β
(0.2 μg/ml; Abcam Limited, Cambridgeshire, UK) or anti-
mouse IL-18 (1:250, kindly provided by Dr. Dinarello)
rabbit polyclonal antibodies. Immunoreactivity was visu-
alized with enhanced chemiluminescence (ECL; Amer-
sham, U.K.) by using peroxydase-conjugated goat anti-
rabbit IgG (1:2,000; Sigma) as secondary antibodies. Den-
sitometric analysis of immunoblots was done to quan-
tify the changes in protein levels (AIS image analyzer;
Imaging Research Inc., St. Catherines, Ontario, Canada)
by using film exposures with maximal signals below the
photographic saturation point. Optical density values in
each sample were normalized by using the corresponding
amount of α-actin.
Organotypic hippocampal slice cultures
Hippocampal slice cultures were prepared from 7-day-
old C57BL/6 mice (Charles River, Calco, Italy), according
to the interface culture method (17) with some modifica-
tions (18). In brief, mice were killed by decapitation, the
brains removed under sterile conditions, and the two hip-
pocampi isolated and cut in transverse sections at 350 μm,
using a McIlwain tissue chopper. Individual slices were
placed in ice-cold Gey’s balanced salt solution (GBSS;
Biological Industries, Kibbuts Beit Haemek, Israel) sup-
plemented with 25 mM D-glucose (Merck, Germany); then
they were placed on semiporous inserts membranes (6
slices on each membrane; Millipore Corp., Bedford, MA,
U.S.A.) and transferred to 6-well culture trays (Corning
Costar, Corning, NY, U.S.A.). Each membrane was im-
mersed in a well containing 1 ml culture medium com-
posed of 50% Opti-MEM, 25% heat-inactivated horse
serum, and 25% Hank’s balanced salt solution (HBSS)
(Gibco BRL, Life Technologies Ltd., East Kilbride,
Lanarkshire, Scotland, U.K.) and supplemented with 25
mM D-glucose. The cultures were incubated for 2 weeks
with 5% CO2 and 95% atmospheric air at 33◦C, and
medium was changed twice a week; no antibiotics or an-
timitotics were used. On the day of the experiment, the
culture medium was replaced with 1 ml of chemically
defined, serum-free Neurobasal medium with 1 mM L-
glutamine and B27 supplement (Gibco BRL, Life Tech-
nologies Ltd).
Inflammatory stimuli were provided to organotypic
slice cultures by preexposure to 10 ng/ml LPS (Es-
cherichia coli serotype 055:B5; Sigma-Aldrich) for 3 h
followed by 3 h coincubation with 1 mM ATP (Sigma-
Aldrich). Previous evidence in human monocytes has
shown that this protocol is required for inducing both the
production and the release of the mature and biologically
active form of IL-1β (19). To investigate the effect of
caspase-1 inhibitors on IL-1β production and subsequent
release, slice cultures were preexposed to 0.1–10 μM pral-
nacasan or VX-765 for 2 h followed by coexposure with
LPS for 3 h and LPS+ATP for a further 3 h.
Organotypic slices not exposed to drugs were used
as controls in every experiment. At the end of the
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experiments, tissue was pooled from six wells per experi-
mental group, whereas the respective culture media were
collected separately. All samples were stored at –70◦ C
until assayed by ELISA.
ELISA
Hippocampal slices were homogenized in 0.5 ml ice-
cold PBS (pH 7.4) containing a mixture of protease in-
hibitors (Roche Biochemical, Indianapolis, IL, U.S.A.),
and 2% of NP-40 (Sigma-Aldrich). The homogenates
were centrifuged, and the supernatants were collected to
measure IL-1β in the tissue.
IL-1β was measured in tissue and medium by using
an ELISA kit (R&D Systems, Minneapolis, MN, U.S.A.)
containing an antibody selective against murine IL-1β that
recognises both pro-IL-1β and the mature form of IL-1β.
The cytokine was measured according to manufacture’s
suggested protocol. Absorbance was read at 405 nm. The
detection limit was <3 pg/ml.
Statistical analysis of data
Data are represented as the mean ± SEM (n, number of
individual samples). The effects of treatments were ana-
lyzed by two-way ANOVA followed by Fisher’s test (for
Western blot data), or by one-way ANOVA followed by
Bonferroni’s test (for organotypic cultures), or by one-way
ANOVA followed by Tukey’s test (for seizure analysis).
RESULTS
Effects of caspase-1 inhibition on hippocampal IL-1β
In vitro evidence
It has been well established in cells of the immune sys-
tem that LPS transcriptionally activates the IL-1β gene,
resulting in enhanced production of IL-1β. However, in
the presence of a second stimulus such as ATP, caspase-1
is activated enzymatically to process pro-IL-1β to the ma-
ture and releasable IL-1β form (17 kDa) (19). We applied
this protocol to mouse organotypic slice cultures to study
the effects of caspase-1 inhibitors on the levels and release
of IL-1β in hippocampal tissue.
Figure 1A and B shows that in organotypic hippocam-
pal slice cultures, ATP is required for inducing a massive
IL-1β release in the presence of LPS, as previously shown
in human monocytes (19). Thus LPS alone increased IL-
1β release into the culture medium by ∼20-fold (p <
0.01), whereas addition of ATP increased IL-1β release
by ∼60-fold compared with control untreated slices (panel
A, p < 0.01 vs. LPS alone). Two hours of preincubation
with pralnacasan or VX-765 reduced in a dose-dependent
manner the LPS+ATP-mediated release of IL-1β in the
medium, reaching the levels observed when slices were
incubated with LPS alone (panel A). Maximal 70% in-
hibition was reached with a concentration of 1 μM for
both inhibitors. In the corresponding tissue extracts, LPS
or the coexposure to LPS+ATP increased IL-1β levels
to a similar extent (p < 0.01 vs. control slices; panel B)
and pralnacasan or VX-765 did not affect LPS+ATP in-
duced increase (panel B). The basal levels of IL-1β in the
medium and in the tissue of control slices (not exposed
to any treatment) were barely or not detectable and did
not differ from those measured in the presence of ATP
or pralnacasan and VX-765 alone. Although the ELISA
method used to measure IL-1β in the tissue and in the
medium does not permit distinguishing between pro-IL-
1β and the mature 17-kDa cytokine, it is well established
that >90% of the releasable form of IL-1β consists of the
17-kDa mature form, whereas the tissue content is mostly
represented by pro-IL-1β (20).
In vivo evidence
Figure 1C and D shows the effect of pralnacasan on
IL-1β levels induced in the rat hippocampus by seizures.
Western blot analysis allowed distinguishing between the
immature (pro-IL-1β, 30 kDa) and the mature and re-
leasable form of IL-1β (17 kDa) (panel D). Seizures in-
creased pro-IL-1β by 84% and the mature and releasable
form of IL-1β by 20%. Anticonvulsant doses of pral-
nacasan (see later) fully reversed the effect of kainic acid–
induced seizures on the mature, releasable form of IL-1β
(p < 0.01 vs. kainic acid), producing a total reduction of
50% below basal levels; consequently, pro-IL-1β was in-
creased by ∼50% above the levels induced by seizures
(p < 0.01 vs. kainic acid). In control hippocampi, pral-
nacasan alone did not significantly affect pro-IL-1β while
reducing mature IL-1β levels by 30% below basal values
(panel C).
IL-18 immunoreactivity was also assessed by using
Western blot analysis because this cytokine is a substrate
of caspase-1 (21). However, no signal was detected in
hippocampal homogenates either in basal conditions or
during seizure activity. The lack of signal was not due to
failure of the Ab, because our Ab detected a specific band
of 18 kDa when tested against 1 μg of human or rodent
recombinant IL-18.
Effects of caspase-1 inhibition on kainic acid-induced
seizures
Pralnacasan
Figure 2A shows the effect of two consecutive icv in-
jections of pralnacasan on kainic acid–induced seizures
in freely moving rats (25 μg in 4 μl given 45 and 10 min
before kainic acid injection). Pralnacasan significantly de-
layed the time to seizure onset by twofold (p < 0.01) and
reduced the number of seizures by 20% (p < 0.01) and
the total time spent in EEG seizures by 40% (p < 0.01).
The average duration of seizures was also significantly re-
duced by 25% by pralnacasan (Vehicle, min, 1.6 ± 0.09;
Pralnacasan, 1.2 ± 0.07∗∗, n = 8; ∗∗p < 0.01 by Student’s
t test). Pralnacasan did not affect seizures when given in a
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FIG. 1. Effects of pralnacasan and VX-765 on hippocampal IL-1β levels A, B: Bargrams show IL-1β levels (mean ± SEM, n = 6) in
mouse organotypic hippocampal slice culture media (A) and extracts (B), as assessed by ELISA. Slices were exposed for 3 h to 10 ng/ml
lipopolysaccharide (LPS) followed by 3 h coincubation wih 1 mM adenosine triphosphate (ATP), or they were incubated for 6 h with LPS
alone. Slices were preincubated with pralnacasan or VX-765 (0.1, 1, and 10 μM) for 2 h and for a subsequent 3 h with LPS, followed by
3 h exposure with LPS+ATP. Control cultures were not exposed to drugs. ∗∗p < 0.01 versus control; #p < 0.01 versus LPS; ◦p < 0.01
versus LPS+ATP by one-way ANOVA followed by Bonferroni’s test (F = 45.4). C, D: Bargrams show the IL-1β levels (mean ± SEM, n =
3) measured in the rat hippocampus in the various experimental conditions, as assessed by Western blot. C: Quantification of the optical
density (OD) of the IL-1β protein bands of 30 kDa (pro-IL-1β) and 17 kDa (mature IL-1β) normalized to the corresponding α-actin levels
(D). Data are expressed as percentage of normalized OD values measured in vehicle-treated rats. ∗p < 0.05; ∗∗p < 0.01 vs. vehicle; #p <
0.01 vs. KA; IL-1β (30 kDa): F(3, 6) = 53.8; IL-1β (17 kDa): F(3, 10) = 10.6 by two-way ANOVA followed by Fisher test. D: Representative
Western blots of pro-IL-1β (30 kDa) and mature (17 kDa) IL-1β in the rat hippocampus in the various experimental conditions. Vehicle:
control rats injected with cremophor icv +PBS intrahippocampally (ih); pralnacasan: rats injected with pralnacasan (2 x 25 μg icv, 45 and
10 min before PBS ih); KA: rats injected with cremophor icv + 40 ng kainic acid ih; KA+pralnacasan: rats injected with pralnacasan 2 x
25 μg icv, 45 and 10 min before kainic acid ih. All rats were killed 90 min after the onset of kainic acid seizures or after the injection of
PBS (vehicle and pralnacasan groups). Each sample was run in duplicate (150 μg protein).
single administration (12.5 or 25 μg in 4 μl given 45 min
before kainic acid) or at doses < 25 μg (12.5 μg in 4 μl
given 45 and 10 min before kainic acid; data not shown).
Pralnacasan inhibited seizure duration by 52% and 38%
of control values during the first and second hour of EEG
recordings, respectively, while its effect faded away dur-
ing the third hour of recording. Pralnacasan did not affect
spiking activity (not shown).
VX-765
Figure 2B shows the effect of systemic administration
of VX-765 on kainic acid–induced seizures. VX-765 at
doses of 25, 50, and 200 mg/kg significantly delayed the
time to seizure onset by 1.5- to twofold (p < 0.01), reduced
the number of seizures by 40% (p < 0.01) and the total
time spent in EEG seizure activity by 30 to 50% (p <
0.01). No differences in spiking activity were observed
(not shown).
The extent of neuronal cell loss induced by kainic acid
in the CA3 area of the injected hippocampus was similar in
pralnacasan- or VX-765–treated rats and their respective
controls (not shown).
Seizure susceptibility in caspase-1 knockout (KO)
mice
Figure 3B shows that the occurrence of seizures induced
by intrahippocampal injection of 14 ng kainic acid was sig-
nificantly delayed by approximately fourfold (p < 0.01) in
caspase-1 KO mice versus their wild-type controls. The
number and total time spent in seizure was reduced by
∼70% (p < 0.01) in caspase-1 KO mice versus wild-type
mice, resulting in decreased incidence of seizures dur-
ing the recording period, but not in their average duration
(see EEG trace in A). Spiking activity was not affected in
caspase-1 KO versus wild-type mice.
Seizure onset in C57BL6/SV129 mice (678 ± 71 s) was
significantly delayed (threefold) by pralnacasan (25 μg,
icv, 45 min and 10 min before kainic acid), which also
reduced the duration of seizures (97 ± 25 s) in mice by
∼70% (p < 0.01). Pralnacasan did not affect any seizure
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FIG. 2. Effects of caspase-1 inhibition on kainic acid–induced seizures in rats A: Pralnacasan (2 x 25 μg in 4 μl 20% cremophor in PBS,
n = 8 rats) or its vehicle (n = 7) was injected intracerebroventricularly, 45 min and 10 min before the intrahippocampal injection of 40 ng
kainic acid in 0.5 μl PBS. B: VX-765 (25, 50, and 200 mg/kg dissolved in 20% cremophor in PBS, n = 8 rats in each group) or its vehicle
(n = 15) was injected intraperitoneally for 3 consecutive days. On day 4, rats received VX-765 or vehicle, 45 min and 10 min before the
intrahippocampal injection of 40 ng kainic acid in 0.5 μl PBS. EEG activity was recorded continously in freely moving rats for 30 min before
(baseline) and for 180 min after the injection of the convulsant. Seizure parameters are defined in the Methods section. Data represent
the mean ± SEM of the various seizure parameters expressed as percentage of control values measured in vehicle-treated rats. Vehicles
in pralnacsan- or VX-765–treated rats were pooled in a unique control group because they did not differ significantly [Onset (min): 7.9 ±
0.7; Number of seizures: 32 ± 1; Time in seizures (min): 44.0 ± 2.0, n = 22]. ∗∗p < 0.01 versus vehicle by one-way ANOVA followed by
Tukey’s test; statistical analysis was done on absolute values.
parameter in caspase-1 KO mice, supporting that its anti-
convulsant activity was specifically mediated by caspase-1
inhibition (not shown).
DISCUSSION
The main finding of this work is that inhibition of
caspase-1 in the brain provides significant protection from
acutely induced seizures in rodents. This anticonvulsive
effect was achieved either after intracerebral or after sys-
temic administration of selective caspase-1 blockers and
was associated with the ability of these drugs to pre-
vent seizure-induced increase of the biologically active
form of IL-1β. The significant involvement of caspase-
1 in seizures is strongly supported by the drastic reduc-
tion in seizure susceptibility observed in mice with dele-
tion of the caspase-1 gene. Although wild-type and KO
mice were bred separately, differences in their seizure
susceptibility are unlikely because of the existence of dif-
ferent genetic backgrounds. Both the wild-type and KO
mice originate from breeding couples of the same genetic
background and derive from a similar number of genera-
tions. Moreover, reported differences in seizure suscepti-
bility to kainic acid among mouse strains (22,23) concern
specifically the mortality rate, behavioral seizures sever-
ity score, and neurodegeneration, and not the duration of
seizures, which is the parameter significantly reduced in
caspase-1 KO versus wild-type mice. Similarly, the onset
to kainate-induced hippocampal EEG seizures is indepen-
dent of the mouse strain as assessed in C57BL6, 129SV,
and C57BL6x129SV mice (unpublished observation).
Caspase-1 inhibition or gene deletion significantly re-
duced ictal activity without changing interictal spiking;
this effect was observed also after intrahippocampal injec-
tion of IL-1Ra or in mice overexpressing IL-1Ra in astro-
cytes (6,9). It is possible that a reduction in IL-1β actions
impairs the transition between interictal and ictal events,
although some level of hippocampal hyperexcitability still
persists. Similarly, classic AEDs such as phenytoin and
carbamazepine provide seizure control without modifying
interictal epileptiform activity in limbic structures (24).
The caspase-1 gene codes for a 45-kDa inactive precur-
sor protein that is constitutively expressed in various cell
types, including glia and neurons (25–27). This precursor
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FIG. 3. Seizure susceptibility in caspase-1 knockout (KO) mice
Traces in A represent baseline recording (a, before kainic acid
injection), typical ictal episode (b) and spiking activity (c), in wild-
type and caspase-1 KO mice. EEG recordings were run continu-
ously for 180 min after convulsant injection. Horizontal bar: 5 s.
Bargrams in B show quantification of the EEG recordings. Data
represent the mean ± SEM (n = 8–11 mice in each experimental
group) of the various seizure parameters expressed as percent-
age of the respective control values. Caspase-1 KO mice and their
respective controls were injected in the hippocampus unilaterally
with kainic acid (14 ng) . ∗p < 0.01 versus wild-type mice by Stu-
dent’s t test. Statistical analysis of data was done on absolute
values.
requires two internal cleavages before becoming the en-
zymatically active mature enzyme. Mature caspase-1 con-
tributes to autoprocessing of its precursor protein by un-
dergoing oligomerization with itself or other members of
the caspase family, such as caspase-3 (28). Unlike other
caspases, caspase-1 is specifically required for processing
the inactive pro-IL-1β and pro-IL-18 to active IL-1β and
IL-18, respectively (29). This process is followed by se-
cretion of the mature cytokines from the cell through an
as-yet-unknown mechanism.
In this study, pharmacologic inhibition of caspase-1 was
achieved in rodent brain by using pralnacasan or VX-
765, representing a new class of protease inhibitors that
specifically inhibit caspase-1. Pralnacasan is a prodrug
of the potent, selective, nonpeptide competitive inhibitor
RU36384, and was the first caspase-1 inhibitor to enter
clinical development. VX-765 is a prodrug with improved
oral bioavailability that is currently under clinical devel-
opment for the treatment of inflammatory and autoim-
mune conditions without any ensuing signs of toxicity, as
reported to date (12,14,30). The powerful anticonvulsant
effect achieved in rats after peripheral administration of
VX-765 opens the perspective of a clinical use of selective
caspase-1 inhibitors for controlling seizures.
Our biochemical evidence indicates that both pral-
nacasan and VX-765 blocked the release of IL-1β induced
by activation of caspase-1 in organotypic hippocampal
slice cultures, thus establishing a proof-of-concept that
these drugs should block also the production and subse-
quent release of mature IL-1β in vivo. In our experimental
model of seizures, we indeed found that an anticonvul-
sant dose of pralnacasan led to a 50% reduction in the
hippocampal levels of the 17-kDa mature form of IL-1β
induced by seizures (1,3,4,7,25). However, residual IL-
1β still remained in the hippocampus in the absence of
caspase-1 activity, suggesting the existence of a pool with
a slow turnover rate. Moreover, other enzymes such as
matrix metalloproteinases, elastase, cathepsins, trypsin, or
chymotrypsin, are able to process to some extent pro-IL-
1β, and this might also be the reason for the residual IL-1β
levels in pralnacasan-treated rats (31–33). In this respect,
we found that caspase-1 inhibition does not affect CA3
pyramidal cell loss in kainate-injected rat hippocampi. It
might be that the residual pool of mature IL-1β is sufficient
to sustain kainate toxicity in spite of significant seizure re-
duction. Indeed, it has been reported that kainate-induced
damage in CA3 depends on a direct neurotoxic action of
kainate rather than on seizures per se (34,35). Alterna-
tively, kainate-induced cell loss may be insensitive to the
proneurotoxic actions of IL-1β which have been demon-
strated so far on NMDA and AMPA-mediated toxicity
only (36–38) .
Our findings strongly suggest that the reduction of IL-
1β levels induced by pralnacasan or VX-765 is responsible
for the anticonvulsive effects of these caspase-1 inhibitors
in rodents. We cannot exclude that these drugs also re-
duced the production of IL-18 in the brain. However, we
could not detect measurable levels of this cytokine in hip-
pocampal homogenates either in control conditions or dur-
ing the acute phases of seizures.
Some antiinflammatory treatments have been shown to
reduce seizures in experimental models (39–41) and in
some instances in humans (42), supporting the concept
that inflammation in the brain is significantly implicated
in the mechanisms of hyperexcitability. Of particular in-
terest for seizure phenomena are the functional interac-
tions between IL-1β and glutamate-mediated neurotrans-
mission. Thus IL-1β increases glutamate release (43),
inhibits its reuptake by glia (44), and enhances NMDA-
mediated calcium influx into pyramidal neurons by in-
ducing tyrosine phosphorylation of NR2B subunit (36).
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These actions anticipate a proexcitatory effect of this cy-
tokine and support its proconvulsant actions as described
in vivo (3,4,6,10).
Clinical evidence linking IL-1β to epilepsy also exists:
caspase-1 and IL-1 are elevated in temporal lobe tissue
of patients with intractable epilepsy (45–47) and a poly-
morphism in the promoter region of the IL-1β gene is
associated with therapy-resistant epilepsy (48,49). This
polymorphism, when present in homozygotes, appears to
predispose to an enhanced production of IL-1β. Moreover,
prominent inflammation in brain has been demonstrated
in disease states associated with the subsequent develop-
ment of intractable seizures (50,51).
Because IL-1β exacerbates seizures and neuronal loss
after various injuries, inhibits neurogenesis, and increases
the blood–brain barrier permeability (38,52–54), pharma-
cologic approaches specifically targeted to block the over-
production of IL-1β or its function(s) in diseased condi-
tions may represent new, nonconventional strategies for
the treatment of seizure disorders.
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